OMNISCAN
Drug
GE HEALTHCARE
Total Payments
$277,635
Transactions
50
Doctors
4
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2022 | $57,738 | 2 | 0 |
| 2020 | $405.00 | 1 | 1 |
| 2019 | $14,348 | 12 | 0 |
| 2018 | $33,342 | 24 | 0 |
| 2017 | $171,802 | 11 | 3 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $149,991 | 42 | 54.0% |
| Consulting Fee | $96,500 | 4 | 34.8% |
| Travel and Lodging | $30,739 | 3 | 11.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $405.00 | 1 | 0.1% |
Payments by Type
Research
$149,991
42 transactions
General
$127,644
8 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| QUANTITATIVE CBF AND BLOOD BRAIN BARRIER PERMEABILITY IMAGING | GE HEALTHCARE | $52,738 | 0 |
| LONG-TERM RETENTION OF GADOLINIUM IN BONE | GE HEALTHCARE | $41,813 | 0 |
| EXPLORATORY EVALUATION OF THE POTENTIAL FOR LONGTERM RETENTION OF GADOLINIUM IN THE BONES OF PATIENTS WHO HAVE RECEIVED GADOLINIUM BASED CONTRAST AGENTS ACCORDING TO THEIR MEDICAL HISTORY | GE HEALTHCARE | $40,927 | 0 |
| EXPLORATORY EVALUATION OF THE POTENTIAL FOR LONGTERM RETENTION OF GADOLINIUM IN THE BONES OF PATIENTS WHO HAVE RECEIVED GADOLINIUM BASED CONTRAST AGENTS ACCORDING TO THEIR MEDICAL HISTORY | GE Healthcare | $6,763 | 0 |
| EFFECTS OF ISO-OSMOLAR VERSUS LOW-OSMOLAR CONTRAST MEDIA ON OUTCOMES OF PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION | GE HEALTHCARE | $5,000 | 0 |
| EARLY STAGE CHRONIC KIDNEY DISEASE IN HIV INFECTED INDIVIDUALS | GE HEALTHCARE | $2,590 | 0 |
| MEASUREMENT OF PULMONARY TRANSIT TIME BY ECHOCARDIOGRAPHY COMPARRISON WITH CARDIAC MRI | GE HEALTHCARE | $161.00 | 0 |
Top Doctors Receiving Payments for OMNISCAN
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Los Angeles, CA | $149,991 | 42 |
| , MD, PHD, FACR | Diagnostic Radiology | New York, NY | $74,983 | 4 |
| , DO | Cardiovascular Disease | Portland, OR | $43,285 | 2 |
| , M. D | Family Medicine | Duluth, MN | $8,971 | 1 |
| , M.D | Diagnostic Radiology | Baltimore, MD | $405.00 | 1 |
Ad
Manufacturing Companies
- GE HEALTHCARE $270,872
- GE Healthcare $6,763
Product Information
- Type Drug
- Total Payments $277,635
- Total Doctors 4
- Transactions 50
About OMNISCAN
OMNISCAN is a drug associated with $277,635 in payments to 4 healthcare providers, recorded across 50 transactions in the CMS Open Payments database. The primary manufacturer is GE HEALTHCARE.
Payment data is available from 2017 to 2022. In 2022, $57,738 was paid across 2 transactions to 0 doctors.
The most common payment nature for OMNISCAN is "Unspecified" ($149,991, 54.0% of total).
OMNISCAN is associated with 7 research studies, including "QUANTITATIVE CBF AND BLOOD BRAIN BARRIER PERMEABILITY IMAGING" ($52,738).